Surya N Mulukutla1, Jean W Hsu2, Ruchi Gaba1, Kurt M Bohren2, Anu Guthikonda1, Dinakar Iyer1, Nadim J Ajami3, Joseph F Petrosino3, Christiane S Hampe4, Nalini Ram1, Farook Jahoor2, Ashok Balasubramanyam1. 1. Diabetes Research Center, Division of Diabetes, Endocrinology and Metabolism. 2. USDA-ARS Children's Nutrition Research Center, Department of Pediatrics; and Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX. 3. Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX. 4. Department of Medicine, University of Washington, Seattle, WA.
Abstract
Background: A-β + ketosis-prone diabetes (KPD) is a subset of type 2 diabetes in which patients have severe but reversible β cell dysfunction of unknown etiology. Plasma metabolomic analysis indicates that abnormal arginine metabolism may be involved. Objective: The objective of this study was to determine the relation between gut microbiome and arginine metabolism and the relation between arginine availability and β cell function in KPD patients compared with control participants. Methods: Kinetics of arginine and related metabolites were measured with stable isotope tracers, and insulin secretory responses to arginine and glucose were determined under euglycemic and hyperglycemic conditions in 6 KPD patients and 6 age-, gender-, and body mass index-matched control participants. Glucose potentiation of arginine-induced insulin secretion was performed in a different set of 6 KPD and 3 control participants. Results: Arginine availability was higher in KPD patients during euglycemia [53.5 ± 4.3 (mean ± SEM) compared with 40.3 ± 2.4 μmol · kg lean body mass (LBM)-1 · h-1, P = 0.03] but declined more in response to hyperglycemia (Δ 10.15 ± 2.6 compared with Δ 3.20 ± 1.3 μmol · kg LBM-1 · h-1, P = 0.041). During hyperglycemia, ornithine flux was not different between groups but after an arginine bolus, plasma ornithine AUC trended higher in KPD patients (3360 ± 294 compared with 2584 ± 259 min · μmol · L-1, P = 0.08). In both euglycemia and hyperglycemia, the first-phase insulin responses to glucose stimulation were lower in KPD patients (euglycemic insulin AUC 282 ± 108 compared with 926 ± 257 min · μU · mL-1, P = 0.02; hyperglycemic insulin AUC 358 ± 79 compared with 866 ± 292 min · μU · mL-1, P = 0.05), but exogenous arginine restored first-phase insulin secretion in KPD patients to the level of control participants. Conclusion: Compared with control participants, KPD patients have increased arginine availability in the euglycemic state, indicating a higher requirement. This is compromised during hyperglycemia, with an inadequate supply of arginine to sustain metabolic functions such as insulin secretion. Exogenous arginine administration restores a normal insulin secretory response.
Background: A-β + ketosis-prone diabetes (KPD) is a subset of type 2 diabetes in which patients have severe but reversible β cell dysfunction of unknown etiology. Plasma metabolomic analysis indicates that abnormal arginine metabolism may be involved. Objective: The objective of this study was to determine the relation between gut microbiome and arginine metabolism and the relation between arginine availability and β cell function in KPDpatients compared with control participants. Methods: Kinetics of arginine and related metabolites were measured with stable isotope tracers, and insulin secretory responses to arginine and glucose were determined under euglycemic and hyperglycemic conditions in 6 KPDpatients and 6 age-, gender-, and body mass index-matched control participants. Glucose potentiation of arginine-induced insulin secretion was performed in a different set of 6 KPD and 3 control participants. Results:Arginine availability was higher in KPDpatients during euglycemia [53.5 ± 4.3 (mean ± SEM) compared with 40.3 ± 2.4 μmol · kg lean body mass (LBM)-1 · h-1, P = 0.03] but declined more in response to hyperglycemia (Δ 10.15 ± 2.6 compared with Δ 3.20 ± 1.3 μmol · kg LBM-1 · h-1, P = 0.041). During hyperglycemia, ornithine flux was not different between groups but after an arginine bolus, plasma ornithine AUC trended higher in KPDpatients (3360 ± 294 compared with 2584 ± 259 min · μmol · L-1, P = 0.08). In both euglycemia and hyperglycemia, the first-phase insulin responses to glucose stimulation were lower in KPDpatients (euglycemic insulin AUC 282 ± 108 compared with 926 ± 257 min · μU · mL-1, P = 0.02; hyperglycemic insulin AUC 358 ± 79 compared with 866 ± 292 min · μU · mL-1, P = 0.05), but exogenous arginine restored first-phase insulin secretion in KPDpatients to the level of control participants. Conclusion: Compared with control participants, KPDpatients have increased arginine availability in the euglycemic state, indicating a higher requirement. This is compromised during hyperglycemia, with an inadequate supply of arginine to sustain metabolic functions such as insulin secretion. Exogenous arginine administration restores a normal insulin secretory response.
Authors: Minerva M Thame; Horace M Fletcher; Tameka M Baker; Juan C Marini; Christina C Kao; Farook Jahoor Journal: J Nutr Date: 2010-11-17 Impact factor: 4.798
Authors: Sanjeet G Patel; Jean W Hsu; Farook Jahoor; Ivonne Coraza; James R Bain; Robert D Stevens; Dinakar Iyer; Ramaswami Nalini; Kerem Ozer; Christiane S Hampe; Christopher B Newgard; Ashok Balasubramanyam Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: A V Kurpad; C Kao; P Dwarkanath; S Muthayya; A Mhaskar; A Thomas; M Vaz; F Jahoor Journal: Eur J Clin Nutr Date: 2009-05-13 Impact factor: 4.016
Authors: Farook Jahoor; Jean W Hsu; Paras B Mehta; Kelly R Keene; Ruchi Gaba; Surya Narayan Mulukutla; Eunice Caducoy; W Frank Peacock; Sanjeet G Patel; Rasmus Bennet; Ake Lernmark; Ashok Balasubramanyam Journal: Diabetes Date: 2021-05-21 Impact factor: 9.337